Acetylcysteine - AstraZeneca

Alternative Names: Mucomyst; N-acetylcysteine; N-Acetylcysteine - AstraZeneca; NAC; NAC - AstraZeneca

Latest Information Update: 05 Aug 2004

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator AstraZeneca
Class Antibronchitics; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
Mechanism of Action Antioxidants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Marketed Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis; Dry eyes; Poisoning

Most Recent Events

15 Mar 2016 Biomarkers information updated
31 Dec 2002 Launched for Bronchiectasis in Australia (Inhalation)
31 Dec 2002 Launched for Chronic obstructive pulmonary disease in Austria (PO)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.